(NASDAQ: NKTR) Nektar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.
Nektar Therapeutics's earnings in 2025 is -$133,041,000.On average, 7 Wall Street analysts forecast NKTR's earnings for 2025 to be -$142,052,339, with the lowest NKTR earnings forecast at -$182,258,360, and the highest NKTR earnings forecast at -$108,685,040. On average, 8 Wall Street analysts forecast NKTR's earnings for 2026 to be -$158,974,203, with the lowest NKTR earnings forecast at -$238,213,786, and the highest NKTR earnings forecast at -$126,487,798.
In 2027, NKTR is forecast to generate -$180,614,437 in earnings, with the lowest earnings forecast at -$303,474,437 and the highest earnings forecast at -$125,186,307.